Cargando…
The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study
BACKGROUND: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer. METHODS: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216037/ https://www.ncbi.nlm.nih.gov/pubmed/25368523 http://dx.doi.org/10.2147/OTT.S68340 |
_version_ | 1782342198971334656 |
---|---|
author | Dong, Min Jun Wang, Lin Bo Jiang, Zhi Nong Jin, Mei Hu, Wen Xian Shen, Jian Guo |
author_facet | Dong, Min Jun Wang, Lin Bo Jiang, Zhi Nong Jin, Mei Hu, Wen Xian Shen, Jian Guo |
author_sort | Dong, Min Jun |
collection | PubMed |
description | BACKGROUND: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer. METHODS: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients – matched for age, clinical tumor–node–metastasis stage, and neoadjuvant chemotherapy cycles – were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis. RESULTS: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013–0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy. CONCLUSION: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-4216037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42160372014-11-03 The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study Dong, Min Jun Wang, Lin Bo Jiang, Zhi Nong Jin, Mei Hu, Wen Xian Shen, Jian Guo Onco Targets Ther Original Research BACKGROUND: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer. METHODS: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients – matched for age, clinical tumor–node–metastasis stage, and neoadjuvant chemotherapy cycles – were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis. RESULTS: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013–0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy. CONCLUSION: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy. Dove Medical Press 2014-10-24 /pmc/articles/PMC4216037/ /pubmed/25368523 http://dx.doi.org/10.2147/OTT.S68340 Text en © 2014 Dong et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Dong, Min Jun Wang, Lin Bo Jiang, Zhi Nong Jin, Mei Hu, Wen Xian Shen, Jian Guo The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
title | The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
title_full | The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
title_fullStr | The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
title_full_unstemmed | The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
title_short | The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
title_sort | transcription factor klf4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case–control study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216037/ https://www.ncbi.nlm.nih.gov/pubmed/25368523 http://dx.doi.org/10.2147/OTT.S68340 |
work_keys_str_mv | AT dongminjun thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT wanglinbo thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT jiangzhinong thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT jinmei thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT huwenxian thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT shenjianguo thetranscriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT dongminjun transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT wanglinbo transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT jiangzhinong transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT jinmei transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT huwenxian transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy AT shenjianguo transcriptionfactorklf4asanindependentpredictivemarkerforpathologiccompleteremissioninbreastcancerneoadjuvantchemotherapyacasecontrolstudy |